0001209191-22-034596.txt : 20220606
0001209191-22-034596.hdr.sgml : 20220606
20220606172700
ACCESSION NUMBER: 0001209191-22-034596
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220602
FILED AS OF DATE: 20220606
DATE AS OF CHANGE: 20220606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Molineaux Christopher P.
CENTRAL INDEX KEY: 0001654773
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 22999018
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 101 LINDENWOOD DRIVE, SUITE 400
CITY: MALVERN
STATE: PA
ZIP: 19355
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 640 LEE ROAD
STREET 2: SUITE 200
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-02
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001654773
Molineaux Christopher P.
C/O ACLARIS THERAPEUTICS, INC.
640 LEE ROAD, SUITE 200
WAYNE
PA
19087
1
0
0
0
Common Stock
2022-06-03
4
M
0
3356
A
27247
D
Stock Option (Right to Buy)
14.48
2022-06-02
4
A
0
15750
0.00
A
2032-06-01
Common Stock
15750
15750
D
Restricted Stock Units
2022-06-02
4
A
0
4507
0.00
A
Common Stock
4507
4507
D
Restricted Stock Units
2022-06-03
4
M
0
3356
0.00
D
Common Stock
3356
0
D
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
This grant was made pursuant to the issuer's seventh amended and restated non-employee director compensation policy.
The shares subject to this option will vest in twelve equal monthly installments commencing July 2, 2022, subject to Reporting Person's continuous service through each such date.
The shares underlying these restricted stock units will vest on June 2, 2023, subject to the Reporting Person's continuous service through such date.
The shares underlying these restricted stock units vested on June 3, 2022.
/s/ Mark Ballantyne, Attorney-in-Fact
2022-06-06